The value of HBsAg quantification in predicting the efficacy of nucleoside (acid) analogue in the treatment of chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001730

Enrollment

Unknown

Registered

2011-11-24

Start date

2007-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

Treatment group:Antiviral Therapy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Chronic hepatitis B; 2. Received nucleoside (acid) analogue treatment.

Exclusion criteria

Exclusion criteria: 1. Presence of other hepatitis virus infection; 2. Presence of human immunodeficiency virus (HIV)infection; 3. With the application of interferon for the treatment of hepatits B; 4. coexisting serious medical disease; advanced liver diseases (including decompensated cirrhosis, severe hepatitis, and hepatic carcinoma).

Design outcomes

Primary

Measure	Time frame
HBV DNA;ALT;Serological response;Resistance rate;	—

Countries

China

Contacts

Public ContactHong Tang

htang6198@hotmail.com+86 18980601313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026